Skip to main content

Table 3 Overall survival

From: Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab

Covariate in model

Patients

HR (Pertuz vs. Control)

HR 95% CI

P value

None

All

0.56

0.22–1.46

0.230

Number prior therapies in Met setting

All

0.57

0.22–1.50

0.257